Xoma Royalty Quick Ratio (XOMA) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Xoma Royalty Corporation  (NASDAQ: XOMA)

Xoma Royalty's Quick Ratio

XOMA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Xoma Royalty's Cash & cash equivalent grew by 3.25 % in the Q1 2026 sequentially, while Current Liabilities decreased, this led to improvement in Xoma Royalty's Quick Ratio to 2.59, Quick Ratio remained below Xoma Royalty Corporation average.

Within Major Pharmaceutical Preparations industry 253 other companies have achieved higher Quick Ratio than Xoma Royalty in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 758 to 993.

Explain Quick Ratio?
How much Cash & cash equivalents XOMA´s has?
What are XOMA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XOMA Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change 51.72 % 34.39 % 25.79 % 7.57 % 28.94 %
Y / Y Cash & cash equivalent Change -5.17 % -18.44 % -68.19 % -47.84 % -33.74 %
Quick Ratio MRQ 2.59 2.02 1.6 3.49 4.14
XOMA's Total Ranking # 993 # 758 # 1107 # 646 # 413
Seq. Current Liabilities Change -19.55 % 45.25 % 31.68 % -1.41 % -28.73 %
Seq. Cash & cash equivalent Change 3.25 % 83.47 % -39.8 % -16.84 % -11.2 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 254
Healthcare Sector # 425
Overall Market # 993


Quick Ratio Statistics
High Average Low
34.97 5.17 0.54
(Sep 30 2021)   (Sep 30 2015)




Financial Statements
Xoma Royalty's Current Liabilities $ 33 Millions Visit XOMA's Balance sheet
Xoma Royalty's Cash & cash equivalent $ 86 Millions Visit XOMA's Balance sheet
Source of XOMA's Sales Visit XOMA's Sales by Geography


Cumulative Xoma Royalty's Quick Ratio

XOMA's Quick Ratio for the trailling 12 Months

XOMA Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth 30.68 % 25.26 % 20.47 % 30.21 % 51.8 %
Y / Y Cash & cash equivalent TTM Growth -39.57 % -43.99 % -45.75 % -12.39 % 34.83 %
Quick Ratio TTM 2.33 2.6 3.05 4.24 5.04
Total Ranking TTM # 3056 # 2409 # 2785 # 2814 # 2712
Seq. Current Liabilities TTM Growth 10 % 10.3 % 6.02 % 1.59 % 5.44 %
Seq. Cash & cash equivalent TTM Growth -1.59 % -6.01 % -23.68 % -14.41 % -8.77 %

Quick ratio ranking by company, industry and sector >> Back to XOMA Financial Strength Comparisons >> Go to Compare XOMA Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q1 2026 to $33.08 millions, cumulative Quick Ratio decreased to 2.33 below the Xoma Royalty Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 401 other companies have achieved higher Quick Ratio than Xoma Royalty. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2409 to 3056.

Explain Quick Ratio?
How much Cash & cash equivalents XOMA´s has?
What are XOMA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 402
Healthcare Sector # 819
Within the Market # 3056


trailing twelve months Quick Ratio Statistics
High Average Low
10.75 4.66 0.79
(Dec 31 2022)   (Jun 30 2017)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Avalo Therapeutics Inc   7.08 $ 82.140  Millions$ 11.599  Millions
Alx Oncology Holdings Inc  6.95 $ 140.324  Millions$ 20.178  Millions
Lyell Immunopharma Inc   6.88 $ 254.023  Millions$ 36.947  Millions
Zymeworks Inc   6.85 $ 244.282  Millions$ 35.649  Millions
Telomir Pharmaceuticals Inc   6.72 $ 5.561  Millions$ 0.827  Millions
Biohaven Ltd   6.68 $ 347.817  Millions$ 52.075  Millions
Silence Therapeutics Plc  6.63 $ 90.590  Millions$ 13.668  Millions
Dermata Therapeutics Inc   6.60 $ 6.945  Millions$ 1.053  Millions
Azitra Inc   6.49 $ 10.051  Millions$ 1.550  Millions
Sionna Therapeutics Inc   6.48 $ 63.324  Millions$ 9.776  Millions
Assembly Biosciences Inc   6.47 $ 226.601  Millions$ 34.997  Millions
Renovorx Inc   6.44 $ 12.362  Millions$ 1.920  Millions
Opus Genetics Inc   6.42 $ 59.959  Millions$ 9.340  Millions
Amarin Corp Plcuk  6.40 $ 308.023  Millions$ 48.153  Millions
Briacell Therapeutics Corp   6.35 $ 22.804  Millions$ 3.590  Millions
Grace Therapeutics Inc  6.35 $ 16.977  Millions$ 2.673  Millions
Annexon Inc   6.26 $ 225.025  Millions$ 35.937  Millions
Tonix Pharmaceuticals Holding Corp   6.26 $ 185.470  Millions$ 29.647  Millions
Arcturus Therapeutics Holdings Inc   6.15 $ 211.375  Millions$ 34.369  Millions
Zentalis Pharmaceuticals Inc   6.01 $ 211.758  Millions$ 35.236  Millions
Camp4 Therapeutics Corporation  5.97 $ 99.209  Millions$ 16.624  Millions
Rocket Pharmaceuticals Inc   5.90 $ 144.379  Millions$ 24.466  Millions
Bridgebio Oncology Therapeutics Inc   5.83 $ 252.275  Millions$ 43.260  Millions
Actinium Pharmaceuticals Inc  5.73 $ 42.132  Millions$ 7.349  Millions
Kura Oncology Inc   5.72 $ 580.823  Millions$ 101.496  Millions
Catalyst Pharmaceuticals Inc   5.71 $ 755.859  Millions$ 132.398  Millions
Cervomed Inc   5.69 $ 12.924  Millions$ 2.272  Millions
Viking Therapeutics Inc   5.67 $ 602.964  Millions$ 106.325  Millions
Kala Bio inc   5.63 $ 8.764  Millions$ 1.557  Millions
Barinthus Biotherapeutics Plc  5.49 $ 65.858  Millions$ 12.001  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.